HC Wainwright Has Optimistic Opinion of RNAC FY2026 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Investment analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Cartesian Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($2.28) per share for the year, up from their prior estimate of ($2.91). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q4 2026 earnings at ($1.05) EPS, Q1 2027 earnings at ($1.08) EPS, Q2 2027 earnings at ($0.94) EPS, Q3 2027 earnings at ($0.81) EPS, Q4 2027 earnings at ($0.82) EPS and FY2027 earnings at ($3.61) EPS.

Cartesian Therapeutics (NASDAQ:RNAC) last posted its earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.63.

RNAC has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cartesian Therapeutics in a research note on Wednesday, September 9th. Needham & Company LLC reissued a “buy” rating and set a $40.00 price objective on shares of Cartesian Therapeutics in a research report on Tuesday, September 29th. Zacks Research upgraded Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Wedbush reaffirmed an “outperform” rating and issued a $38.00 target price on shares of Cartesian Therapeutics in a report on Tuesday, August 18th. Finally, Wall Street Zen raised Cartesian Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Cartesian Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

Cartesian Therapeutics Stock Down 6.8%

NASDAQ RNAC opened at $7.02 on Tuesday. The company has a fifty day simple moving average of $7.35 and a 200 day simple moving average of $7.64. Cartesian Therapeutics has a 1 year low of $5.60 and a 1 year high of $11.00.

Institutional Trading of Cartesian Therapeutics

A number of hedge funds have recently modified their holdings of RNAC. Sei Investments Co. acquired a new stake in shares of Cartesian Therapeutics during the 1st quarter worth approximately $78,000. Bank of New York Mellon Corp acquired a new position in shares of Cartesian Therapeutics in the second quarter valued at $332,000. Renaissance Technologies LLC raised its stake in shares of Cartesian Therapeutics by 63.7% in the first quarter. Renaissance Technologies LLC now owns 67,300 shares of the company’s stock valued at $414,000 after purchasing an additional 26,200 shares in the last quarter. Privium Fund Management B.V. raised its stake in shares of Cartesian Therapeutics by 2.2% in the third quarter. Privium Fund Management B.V. now owns 155,000 shares of the company’s stock valued at $1,118,000 after purchasing an additional 3,325 shares in the last quarter. Finally, Squarepoint Ops LLC raised its stake in shares of Cartesian Therapeutics by 0.7% in the second quarter. Squarepoint Ops LLC now owns 2,254,619 shares of the company’s stock valued at $23,493,000 after purchasing an additional 16,133 shares in the last quarter. Institutional investors own 86.95% of the company’s stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc (NASDAQ: RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to program a patient’s own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification.

Cartesian’s lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA).